Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.

Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

Key brands saw growth in the first half of 2021 despite the company’s overall revenues falling, mainly due to generic competition for Northera.

The effect of low-dose psilocybin, a compound found in mushrooms, on a rare debilitating condition, short-lasting unilateral neuralgiform headaches attacks, is to be evaluated by the 2019-founded UK biotech, Beckley Psytech.